IBD is a dubious disease in the field of infectious respiratory digestive and endocrine disorders, clinical performance is complex and often involves multi-systematic fatigue. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of IBD requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
A comprehensive assessment platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved. Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely schemes according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of IBD-associated inflammation. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.